-
公开(公告)号：US11874532B2
公开(公告)日：2024-01-16
申请号：US17550728
申请日：2021-12-14
CPC分类号： G02C7/086 , G02C2202/16 , G02C2202/20 , G02C2202/24
摘要： The present disclosure is directed generally to a lens that provides a stop signal to a myopic eye, over a substantial portion of the spectacle lens that the viewer is using. The present disclosure is directed to devices, methods and/or systems of imposing a stop signal to eye growth, using a spectacle lens in conjunction with a micro lenslet array. The present disclosure is also directed to devices, methods and/or systems of modifying incoming light through spectacle lenses that utilizes chromatic cues to decelerate the rate of myopia progression. The present disclosure is directed to devices, methods and/or systems of imposing a stop signal to eye growth, using a spectacle lens in conjunction with a refractive optical element and/or diffractive optical element that offer conflicting or contradictory optical signals at a wavelength between 510 nm and 610 nm.
-
公开(公告)号：US11813197B2
公开(公告)日：2023-11-14
申请号：US17555796
申请日：2021-12-20
CPC分类号： A61F9/0017 , A61F2/1637 , A61K31/46 , G02B21/08 , G02C7/021 , G02C7/022 , G02C7/027 , G02C7/04 , A61K9/0051
摘要： An ophthalmic lens for treating myopia comprising: a base lens with a front surface, a back surface, and a first power profile selected to correct or substantially correct for a distance refractive error of the eye; one or more myopia control elements on at least one of the front and back surfaces of the lens; a first viewing region having a dimension selected based, at least in part, on a concentration of a pharmaceutical agent for use in conjunction with an ophthalmic lens, the first viewing region being configured to minimize, reduce and/or eliminate vision disturbances for distance vision; and a second viewing region comprising a power profile that is relatively more positive compared to the first viewing region; wherein at least one of the size of the second viewing region and the relatively more positive power of the second viewing region is selected based, at least in part, on the concentration of the pharmaceutical agent.
-
公开(公告)号：US11644688B2
公开(公告)日：2023-05-09
申请号：US17069549
申请日：2020-10-13
发明人： Ravi Chandra Bakaraju , Klaus Ehrmann , Arthur Ho
CPC分类号： G02C7/061 , A61B3/0025 , A61B3/1015 , A61F2/145 , A61F2/1451 , A61F2/1613 , A61F2/1618 , A61F2/1637 , G02C7/02 , G02C7/022 , G02C7/027 , G02C7/04 , G02C7/041 , G02C7/06 , G02C7/083 , A61F2/14 , A61F2002/1681 , G02C2202/22 , G02C2202/24
摘要： A lens for an eye having an optical axis and an aberration profile along its optical axis, the aberration profile having a focal distance and including higher order aberrations having at least one of a primary spherical aberration component and a secondary spherical aberration component. The aberration profile may provide, for a model eye with no aberrations and an on-axis length equal to the focal distance: a peak, first retinal image quality (RIQ) within a through focus range that remains at or above a second RIQ over the through focus range that includes said focal distance, where the first RIQ is at least 0.35, the second RIQ is at least 0.1 and the through focus range is at least 1.8 Diopters.
-
公开(公告)号：US11567347B2
公开(公告)日：2023-01-31
申请号：US16608562
申请日：2018-04-27
摘要： An ophthalmic lens system for reducing the risk of progression of a myopic eye by selectively maintaining, inducing or creating asymmetry of the peripheral retinal profile for the eye. A method for reducing the risk of progression of myopia comprising determining the magnitude of asymmetry of the on-axis/off-axis refractive error profile or eye length profile of the eye and providing an ophthalmic lens system that corrects for and provides acceptable on-axis vision and simultaneously controls the position of the off-axis refractive error profile or eye length profile such that resultant profile of the eye is asymmetric.
-
公开(公告)号：US20220373824A1
公开(公告)日：2022-11-24
申请号：US17715594
申请日：2022-04-07
发明人： Ravi Bakaraju , Klaus Ehrmann , Arthur Ho , Brien Anthony Holden
摘要： The present disclosure is directed to lenses, devices, methods and/or systems for addressing refractive error. Certain embodiments are directed to changing or controlling the wavefront of the light entering a human eye. The lenses, devices, methods and/or systems can be used for correcting, addressing, mitigating or treating refractive errors and provide excellent vision at distances encompassing far to near without significant ghosting. The refractive error may for example arise from myopia, hyperopia, or presbyopia with or without astigmatism. Certain disclosed embodiments of lenses, devices and/or methods include embodiments that address foveal and/or peripheral vision. Exemplary of lenses in the fields of certain embodiments include contact lenses, corneal onlays, corneal inlays, and lenses for intraocular devices both anterior and posterior chamber, accommodating intraocular lenses, electro-active spectacle lenses and/or refractive surgery.
-
公开(公告)号：US11234862B2
公开(公告)日：2022-02-01
申请号：US17197858
申请日：2021-03-10
摘要： An ophthalmic lens for treating myopia comprising: a base lens with a front surface, a back surface, and a first power profile selected to correct or substantially correct for a distance refractive error of the eye; one or more myopia control elements on at least one of the front and back surfaces of the lens; a first viewing region having a dimension selected based, at least in part, on a concentration of a pharmaceutical agent for use in conjunction with an ophthalmic lens, the first viewing region being configured to minimize, reduce and/or eliminate vision disturbances for distance vision; and a second viewing region comprising a power profile that is relatively more positive compared to the first viewing region; wherein at least one of the size of the second viewing region and the relatively more positive power of the second viewing region is selected based, at least in part, on the concentration of the pharmaceutical agent.
-
公开(公告)号：US20210311327A1
公开(公告)日：2021-10-07
申请号：US17195162
申请日：2021-03-08
发明人： Brien Anthony Holden , Gregor Schmid , Padmaja Rajagopal Sankaridurg , Arthur Ho , Aldo Abraham Martinez Magos , Percy Fabian Lazon , Earl Leo Smith, III
摘要： A contact lens and a method for treating an eye with myopia is described. The contact lens includes an inner optic zone and an outer optic zone. The outer optic zone includes at least a portion with a first power, selected to correct distance vision. The inner optic zone has a relatively more positive power (an add power). In some embodiments the add power is substantially constant across the inner optic zone. In other embodiments the add power is variable across the inner optic zone. While in some embodiments the inner optic zone has a power designed to substantially eliminate lag of accommodation in the eye with myopia, in other embodiments, the add power may be higher.
-
38.发明申请公开(公告)号：US20210286197A1
公开(公告)日：2021-09-16
申请号：US17184141
申请日：2021-02-24
发明人： Brien Anthony Holden , Padmaja Rajagopal Sankaridurg , Klaus Ehrmann , Fabian Conrad , Arthur Ho
摘要： The present disclosure is directed to lens, methods of making, designing lens and/or methods using lens in which performance may be improved by providing one or more steps in the central portion of the optical zone and one or more steps in the peripheral portion of the optic zone. In some embodiments, such lens may be useful for correcting refractive error of an eye and/or for controlling eye growth.
-
公开(公告)号：US20210282966A1
公开(公告)日：2021-09-16
申请号：US17197858
申请日：2021-03-10
摘要： An ophthalmic lens for treating myopia comprising: a base lens with a front surface, a back surface, and a first power profile selected to correct or substantially correct for a distance refractive error of the eye; one or more myopia control elements on at least one of the front and back surfaces of the lens; a first viewing region having a dimension selected based, at least in part, on a concentration of a pharmaceutical agent for use in conjunction with an ophthalmic lens, the first viewing region being configured to minimize, reduce and/or eliminate vision disturbances for distance vision; and a second viewing region comprising a power profile that is relatively more positive compared to the first viewing region; wherein at least one of the size of the second viewing region and the relatively more positive power of the second viewing region is selected based, at least in part, on the concentration of the pharmaceutical agent.
-
40.发明申请公开(公告)号：US20210205256A1
公开(公告)日：2021-07-08
申请号：US16995362
申请日：2020-08-17
发明人： Hua Zhu , Judith Louise Flanagan
IPC分类号： A61K31/23 , A61K38/18 , A61K47/06 , A61K47/24 , A61K47/44 , A61K38/13 , A61K45/06 , A61K9/00 , A61K31/20 , A61K31/5685 , A61K31/7052 , A61K31/202 , A61K31/568
摘要： The present disclosure relates to compositions, methods and devices for treating, reducing or preventing one or more eye disorders, particularly dry eye disorders, in a subject by administering an amount of one or more fatty acids and/or fatty acid esters therapeutically effective to inhibit lipase activity while permitting bacterial growth or without substantially altering the dynamic microbial community of the eye. Typically, the fatty acids and/or fatty acid esters are C8 to C16 fatty acids and/or fatty acid esters.
-
-
-
-
-
-
-
-
-
搜索结果
73 条记录 (耗时 0.03 秒)
